ERK2, but not ERK1, mediates acquired and "De novo" resistance to imatinib mesylate: Implication for CML therapy

PLoS ONE

Volumn 4, Issue 7, 2009, Pages

  Aceves Luquero, Clara I ^a   Agarwal, Anupriya ^b   Calllejas Valera, Juan L ^a   Arias González, Laura ^a   Esparís Ogando, Azucena ^c   Ovalke, Luis del Paso ^d   Bellón Echeverria, Itxaso ^a   de la Cruz Morcillo, Miguel A ^a   Moya, Eva M Galán ^a   Gimeno, Inmaculada Moreno ^a   Gómez, Juan C ^b   Deininger, Michael W ^b   Pandiella, Atanasio ^c   Prieto, Ricardo Sánchez ^a  

^a UCLM   (Spain)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Salamanca Spain   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CHIMERIC PROTEIN; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; CANCER THERAPY; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE MUTATION; HUMAN; HUMAN CELL; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSIENT TRANSFECTION; DOSE RESPONSE; DRUG RESISTANCE; ENZYMOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; METABOLISM; ONCOGENE; POINT MUTATION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENES, ABL; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PIPERAZINES; POINT MUTATION; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 67651241759     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006124     Document Type: Article

References (51)

1. Wong S, Witte ON (2004) The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 22: 247-306.
2. Buschbeck M, Hofbauer S, Di CL, Keri G, Ullrich A (2005) Abl-kinase-sensitive levels of ERK5 and its intrinsic basal activity contribute to leukaemia cell survival. EMBO Rep 6: 63-69.
3. Sanchez-Arevalo LV, Aceves Luquero CI, varez-Vallina L, Tipping AJ, Viniegra JG, et al. (2005) Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. Biochem J 387: 231-238.
4. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, et al. (2008) Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/ STAT pathways to leukemia. Leukemia 22: 686-707.
5. Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640-2653.
6. O'hare T, Eide CA, Deininger MW (2007) Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia. Clin Lymphoma Myeloma 7 Suppl 3: S120-S130.
7. Martinelli G, Soverini S, Rosti G, Baccarani M (2005) Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia 19: 1872-1879.
8. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD (2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7: 345-356.
9. Lange T, Park B, Willis SG, Deininger MW (2005) BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy? Cell Cycle 4: 1761-1766.
10. Sherbenou DW, Wong MJ, Humayun A, McGreevey LS, Harrell P, et al. (2007) Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia 21: 489-493.
11. Melo JV, Chuah C (2007) Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett 249: 121-132.
12. Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, et al. (2002) Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 62: 188-199.
13. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, et al. (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96: 1070-1079.
14. Weisberg E, Griffin JD (2000) Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 95: 3498-3505.
15. Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, et al. (2005) Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 65: 8912-8919.
16. Gaiger A, Henn T, Horth E, Geissler K, Mitterbauer G, et al. (1995) Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 86: 2371-2378.
17. Melo JV, Barnes DJ (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7: 441-453.
18. Esparis-Ogando A, az-Rodriguez E, Montero JC, Yuste L, Crespo P, et al. (2002) Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol 22: 270-285.
19. Agarwal A, Eide CA, Harlow A, Corbin AS, Mauro MJ, et al. (2008) An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia. Leukemia.
20. Galan-Moya EM, Hernandez-Losa J, ceves Luquero CI, de la Cruz-Morcillo MA, et al. (2008) c-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy. Int J Cancer 122: 289-297.
21. de Vries-Smits AM, Burgering BM, Leevers SJ, Marshall CJ, Bos JL (1992) Involvement of p21ras in activation of extracellular signal-regulated kinase 2. Nature 357: 602-604.
22. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J (1994) Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370: 527-532.
23. Burchert A, Wang Y, Cai D, von BN, Paschka P, et al. (2005) Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19: 1774-1782.
24. Montiel-Duarte C, Cordeu L, Agirre X, Roman-Gomez J, Jimenez-Velasco A, et al. (2007) Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation. Leuk Res.
25. Parmar S, Katsoulidis E, Verma A, Li Y, Sassano A, Lal L, et al. (2004) Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J Biol Chem 279: 25345-25352.
26. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, et al. (1995) SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 364: 229-233.
27. Kuma Y, Sabio G, Bain J, Shpiro N, Marquez R, Cuenda A (2005) BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem 280: 19472-19479.
28. Morinaga K, Yamauchi T, Kimura S, Maekawa T, Ueda T (2008) Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCRABL gene amplification. Int J Cancer 122: 2621-2627.
29. Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, et al. (2006) A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10: 425-435.
30. Wong S, McLaughlin J, Cheng D, Witte ON (2003) Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors. Blood 101: 4088-4097.
31. Mayer IA, Verma A, Grumbach IM, Uddin S, Lekmine F, et al. (2001) The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem 276: 28570-28577.
32. Korus M, Mahon GM, Cheng L, Whitehead IP (2002) p38 MAPK-mediated activation of NF-kappaB by the RhoGEF domain of Bcr. Oncogene 21: 4601-4612.
33. D'Souza WN, Chang CF, Fischer AM, Li M, Hedrick SM (2008) The Erk2 MAPK regulates CD8 T cell proliferation and survival. J Immunol 181: 7617-7629.
34. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ (2003) Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 278: 18811-18816.
35. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, et al. (2006) Bim and Bad mediate imatinib-induced killing of Bcr/Abl+leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A 103: 14907-14912.
36. Chu S, Holtz M, Gupta M, Bhatia R (2004) BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 103: 3167-3174.
37. Dan S, Naito M, Tsuruo T (1998) Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of. Cell Death Differ 5: 710-715.
38. Konig H, Holtz M, Modi H, Manley P, Holyoake TL, et al. (2008) Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 22: 748-755.
39. Nguyen TK, Rahmani M, Harada H, Dent P, Grant S (2007) MEK1/2 inhibitors sensitize Bcr/Abl+human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood 109: 4006-4015.
40. Liu E, Hjelle B, Bishop JM (1988) Transforming genes in chronic myelogenous leukemia. Proc Natl Acad Sci U S A 85: 1952-1956.
41. Garicochea B, Giorgi R, Odone VF, Dorlhiac-Llacer PE, Bendit I (1998) Mutational analysis of N-RAS and GAP-related domain of the neurofibromatosis type 1 gene in chronic myelogenous leukemia. Leuk Res 22: 1003-1007.
42. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880.
43. Barnes DJ, Schultheis B, Adedeji S, Melo JV (2005) Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene 24: 6432-6440.
44. Lahaye T, Riehm B, Berger U, Paschka P, Muller MC, et al. (2005) Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 103: 1659-1669.
45. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, et al. (2008) Targeting survival cascades induced by activation of Ras/Raf/MEK/ ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 22: 708-722.
46. Bonhoure E, Lauret A, Barnes DJ, Martin C, Malavaud B, et al. (2008) Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia 22: 971-979.
47. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, et al. (2002) Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1: 479-492.
48. Sonoyama J, Matsumura I, Ezoe S, Satoh Y, Zhang X, et al. (2002) Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells. J Biol Chem 277: 8076-8082.
49. Vantaggiato C, Formentini I, Bondanza A, Bonini C, Naldini L, et al. (2006) ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. J Biol 5: 14.
50. Hwang CY, Lee C, Kwon KS (2009) ERK2-dependent phosphorylation induces cytoplasmic localization and degradation of p21Cip1. Mol Cell Biol.
51. Chang JS, Santhanam R, Trotta R, Neviani P, Eiring AM, Briercheck E, et al. (2007) High levels of the BCR/ABL oncoprotein are required for the MAPKhnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. Blood 110: 994-1003.